Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07327359Phase 1Recruiting

A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

Role: lead

NCT05643118Phase 1Completed

Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration

Role: lead

NCT04877756Phase 2Completed

Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery

Role: lead

NCT05038371Terminated

Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration

Role: collaborator

NCT03569267Phase 1Completed

A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects

Role: lead

All 5 trials loaded